The Latest Cardiac and Vascular News
ROCKVILLE, M.D. and SUZHOU, China, Nov 6, 2022 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the results of a phase 3 clinical study (CREDIT-1) of tafolecimab (IBI306), a […]
Trial met its primary endpoint, with 64.3% of patients receiving etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001) Median time to conversion was 17 minutes for patients treated with etripamil – three times faster than placebo Analyses of pooled data show […]
Olpasiran Reduced Lipoprotein(a) Levels by More Than 95% in Patients With Established ASCVD Amgen is Initiating a Phase 3 Cardiovascular Outcomes Trial Based on These Results Data Simultaneously Published in the New England Journal of Medicine THOUSAND OAKS, Calif. , Nov. 6, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today presented end-of-treatment data from its […]
SHANGHAI , Nov. 7, 2022 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized OTM (From Operating Table to Market) innovative platform, today announced the successful close of its latest financing round. The financing was led by YuanBio Venture Capital, other investors includes Orbimed Healthcare Fund Management, Cenova Capital, Lilly Asia Ventures (LAV), GaoRong […]
SHANGHAI, Nov. 7, 2022 /PRNewswire/ — From November 1, 2022, Mr. Alan Tsai is promoted to the role of General Manager of Cordis Greater China. He will head the leadership team responsible for strategic planning, business operation and team development for Greater China, the fastest growing area in Asia Pacific. Based in Shanghai, he will report directly to Bryan […]
Six-month primate HAV CABG model demonstrates patency, recellularization and remodeling resembling native blood vessels HAV may address many limitations of current standard of care grafts used in CABG procedure DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered […]
Data Demonstrate Orally Inhaled Flecainide May Provide a Safe, Effective, and Convenient First-Line Treatment Option for Cardioversion of Recent-Onset Newly Diagnosed and Paroxysmal Atrial Fibrillation Topline Results from the Ongoing Pivotal Phase 3 RESTORE-1 Trial of InRhythm Expected in Early 2024 SAN FRANCISCO, Nov. 07, 2022 (GLOBE NEWSWIRE) — InCarda […]
A new analysis of iRhythm’s mSToPS trial, presented at the American Heart Association, reveals that Zio® XT provided high value from a health economic perspective SAN FRANCISCO, Nov. 06, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading cardiovascular diagnostics and digital healthcare solutions company focused on creating trusted solutions that […]
— Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore CV Risk Reduction Benefits of Eicosapentaenoic Acid for Patients — — PROMINENT Study Failed to Show CV Risk Reduction Benefit of the Fibrate Class for Statin-Treated High-Risk Patients — DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 07, 2022 […]
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from two additional analyses from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), as well as an analysis of patients hospitalized for heart failure with reduced ejection fraction (HFrEF) from the Get With The Guidelines®-Heart […]
